The structure of DNA was first determined in 1953, but it wasn't until the early 1970s that the first recombinant DNA molecules were produced using restriction enzymes. Paul Berg succeeded in proving the possibility of splicing and recombining genetic material in 1971. Stanley Cohen and Herbert Boyer were able to cut and fuse specifically located DNA strands, leading to the approval of a patent for recombinant antibody technology in 1980.
The first commercial healthcare product derived from rDNA was human insulin. Today, it is successfully used to produce new antibodies, vaccines (e.g., for Hepatitis B), and different protein production systems, such as insulin and human growth hormone.
Here are 5 examples of rDNA technology in the health sector:
Recombinant DNA technology is used to genetically modify plants to improve adaptability, resistance to harmful agents, and enhance product yield.
Examples of rDNA technology in agriculture include:
Recombinant DNA technology enables the manufacturing of novel enzymes to prolong shelf life and kill foodborne pathogens.
Here are 3 examples of recombinant DNA technology in the food industry:
Recombinant DNA technology involves the isolation and manipulation of genetic material to improve certain characteristics. It differs from genetic recombination, which is a natural biological process.
There are three different methods of producing recombinant DNA: transformation, non-bacterial transformation, and phage introduction. These methods involve the insertion of DNA segments into host cells, either with or without the use of bacteria.
The production of recombinant DNA involves the isolation of genetic material, cutting of DNA at specific locations, joining of DNA fragments, insertion into host cells, and selection and screening of transformed cells.
In recombinant DNA technology, DNA sequences from various sources can be used. Enzymes, gene cloning vectors, polymerase chain reaction (PCR), and host organisms are important tools in this field.
Recombinant DNA molecules and recombinant proteins are generally not regarded as dangerous. However, concerns exist regarding the safety of organisms expressing recombinant DNA, particularly in terms of environmental impact and potential health effects.
Recombinant DNA technology plays a vital role in improving health conditions and addressing plant disorders. The global market for recombinant DNA technology is expected to reach USD 223 billion by 2028, with a projected annual growth rate of 7.7%.
181 videos|346 docs
|
|
Explore Courses for UPSC exam
|